Prognostic value of histologic grade and proliferative activity in axillary node-positive breast cancer: Results from the Eastern Cooperative Oncology Group companion study, EST 4189

被引:116
作者
Simpson, JF
Gray, R
Dressler, LG
Cobau, CD
Falkson, CI
Gilchrist, KW
Pandya, KJ
Page, DL
Robert, NJ
机构
[1] Vanderbilt Univ, Med Ctr, Dept Pathol, Nashville, TN 37232 USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Univ N Carolina, Chapel Hill, NC USA
[4] Flower Mem Hosp, Sylvania, OH USA
[5] Univ Pretoria, ZA-0002 Pretoria, South Africa
[6] Univ Wisconsin, Ctr Comprehens Canc, Madison, WI USA
[7] Univ Rochester, Ctr Canc, Rochester, NY USA
[8] Fairfax Hosp, Falls Church, VA 22046 USA
关键词
D O I
10.1200/JCO.2000.18.10.2059
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: The identification of a subset of patients with axillary lymph node-positive breast cancer with an improved prognosis would be clinically useful. We report the prognostic importance of histologic grading and proliferative activity in a cohort of patients with axillary lymph node-positive breast cancer and compare these parameters with other established prognostic factors. Patients and Methods: This Eastern Cooperative Oncology Group laboratory companion study (E4189) centered on 560 axillary lymph node-positive patients registered onto one of six eligible clinical protocols. Flow cytometric (ploidy and S-phase fraction [SPF]) and histopathologic analyses (Nottingham Combined Histologic Grade and mitotic index) were performed on paraffin-embedded tissue from 368 patients. Results: Disease recurred in 208 patients; in 161 (77%), within the first 5 years. Mitotic index and grade were associated with both ploidy and SPF (P less than or equal to.01). Within the first 5 years of follow-up, mitotic index (P =.004), grade (P =.004), ploidy (P =.006), and SPF (P =.05) were associated with time to recurrence; there was also a significant association with survival. The effect of mitotic index was largely a result of the difference between 0 to 2 mitoses/10 high-power fields (HPF; 5-year recurrence of 31%) and more than 2 mitoses/10 HPF (5-year recurrence of 52%). The 0 to 2 mitoses/10 HPF group was independently associated with improved prognosis at 5 years (P =.002) in regression models that included other standard prognostic factors. Conclusion: A subset of axillary lymph node-positive patients with improved prognosis may be identified using a lower (< 3 mitoses/10 HPF) mitotic count than is usually performed. J Clin Oncol 18:2059-2069. (C) 2000 by American Society of Clinical Oncology.
引用
收藏
页码:2059 / 2069
页数:11
相关论文
共 51 条
[1]   MITOSIS COUNTING IN TUMORS [J].
BAAK, JPA .
HUMAN PATHOLOGY, 1990, 21 (07) :683-685
[2]   COMBINATION CHEMOTHERAPY AS AN ADJUVANT TREATMENT IN OPERABLE BREAST-CANCER [J].
BONADONNA, G ;
BRUSAMOLINO, E ;
VALAGUSSA, P ;
ROSSI, A ;
BRUGNATELLI, L ;
BRAMBILLA, C ;
DELENA, M ;
TANCINI, G ;
BAJETTA, E ;
MUSUMECI, R ;
VERONESI, U .
NEW ENGLAND JOURNAL OF MEDICINE, 1976, 294 (08) :405-410
[3]   Tumor proliferative activity and response to first-line chemotherapy in advanced breast carcinoma [J].
Bonetti, A ;
Zaninelli, M ;
Rodella, S ;
Molino, A ;
Sperotto, L ;
Piubello, Q ;
Bonetti, F ;
Nortilli, R ;
Turazza, M ;
Cetto, GL .
BREAST CANCER RESEARCH AND TREATMENT, 1996, 38 (03) :289-297
[4]  
CARRIAGA MT, 1995, CANCER-AM CANCER SOC, V75, P406, DOI 10.1002/1097-0142(19950101)75:1+<406::AID-CNCR2820751322>3.0.CO
[5]  
2-W
[6]   PROGNOSTIC-SIGNIFICANCE OF S-PHASE FRACTION IN GOOD-RISK, NODE-NEGATIVE BREAST-CANCER PATIENTS [J].
CLARK, GM ;
MATHIEU, MC ;
OWENS, MA ;
DRESSLER, LG ;
EUDEY, L ;
TORMEY, DC ;
OSBORNE, CK ;
GILCHRIST, KW ;
MANSOUR, EG ;
ABELOFF, MD ;
MCGUIRE, WL .
JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (03) :428-432
[7]  
CLAYTON F, 1991, CANCER, V68, P1309, DOI 10.1002/1097-0142(19910915)68:6<1309::AID-CNCR2820680621>3.0.CO
[8]  
2-I
[9]  
*CONS DEV PAN, 1992, J NCI MONOGR, V11, P1
[10]   THE IMPORTANCE OF HISTOLOGIC GRADE IN LONG-TERM PROGNOSIS OF BREAST-CANCER - A STUDY OF 1,010 PATIENTS, UNIFORMLY TREATED AT THE INSTITUT-GUSTAVE-ROUSSY [J].
CONTESSO, G ;
MOURIESSE, H ;
FRIEDMAN, S ;
GENIN, J ;
SARRAZIN, D ;
ROUESSE, J .
JOURNAL OF CLINICAL ONCOLOGY, 1987, 5 (09) :1378-1386